Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2005.02.8282 on December 12 2005

Journal of Clinical Oncology, Vol 24, No 2 (January 10), 2006: pp. 252-258
© 2006 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gold, D. V.
Right arrow Articles by Goldenberg, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gold, D. V.
Right arrow Articles by Goldenberg, D. M.

New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From Pancreatitis

David V. Gold, David E. Modrak, Zhiliang Ying, Thomas M. Cardillo, Robert M. Sharkey, David M. Goldenberg

From the Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville; Immunomedics Inc, Morris Plains, NJ; and the Department of Statistics, Columbia University, New York, NY

Address reprint requests to David V. Gold, PhD, Garden State Cancer Center, 520 Belleville Ave, Belleville, NJ 07109; e-mail: dvgold{at}gscancer.org

PURPOSE: To evaluate a new immunoassay for identification and quantitation of MUC1 in the sera of patients with pancreatic cancer or pancreatitis. The sensitivity and specificity of the assay are examined and compared to results from a CA19-9 immunoassay.

METHODS: An in vitro enzyme immunoassay was established with monoclonal antibody PAM4 as the capture reagent, and a polyclonal anti-MUC1 antibody as the probe. Patient sera were obtained from healthy, adult patients with acute and chronic pancreatitis, and those with pancreatic and other forms of cancer, and were measured for PAM4-reactive MUC1.

RESULTS: At a cutoff of 10.2 units/mL, 41 (77%) of 53 pancreatic cancer patients, none of the healthy individuals (n = 43), and only four (5%) of 87 patients with pancreatitis were positive above this value. Among nonpancreatic cancers investigated, colorectal cancers gave the highest percentage of positives (14%; five of 36). Overall, the sensitivity and specificity of the immunoassay for pancreatic cancer were 77% and 95%, respectively. Receiver operator characteristic analyses for discrimination of pancreatic cancer from pancreatitis provided an area under the curve of 0.89 (95% CI, 0.82 to 0.93), with a specificity of 95.4% and a positive likelihood ratio of 16.8. A direct pair-wise comparison of PAM4 and CA19-9 immunoassays for discrimination of pancreatic cancer and pancreatitis resulted in a significant difference (P < .003), with the PAM4 immunoassay demonstrating superior sensitivity and specificity.

CONCLUSION: The high sensitivity and specificity observed suggest that the PAM4-based immunoassay of circulating MUC1 may be useful in the diagnosis of pancreatic cancer.

Supported in part by grants CA92723 and CA98488 from the National Institutes of Health (Bethesda, MD).

Presented in part at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
Cancer Res.Home page
D. V. Gold, D. M. Goldenberg, H. Karacay, E. A. Rossi, C.-H. Chang, T. M. Cardillo, W. J. McBride, and R. M. Sharkey
A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma
Cancer Res., June 15, 2008; 68(12): 4819 - 4826.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. V. Gold, Z. Karanjawala, D. E. Modrak, D. M. Goldenberg, and R. H. Hruban
PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma
Clin. Cancer Res., December 15, 2007; 13(24): 7380 - 7387.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
G. Kroemer, L. Galluzzi, and C. Brenner
Mitochondrial Membrane Permeabilization in Cell Death
Physiol Rev, January 1, 2007; 87(1): 99 - 163.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
W. J. McBride, P. Zanzonico, R. M. Sharkey, C. Noren, H. Karacay, E. A. Rossi, M. J. Losman, P.-Y. Brard, C.-H. Chang, S. M. Larson, et al.
Bispecific Antibody Pretargeting PET (ImmunoPET) with an 124I-Labeled Hapten-Peptide
J. Nucl. Med., October 1, 2006; 47(10): 1678 - 1688.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online